Targeted compound daraxonrasib successfully blocks multiple KRAS variants to double survival limits in clinical trials.

Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS, and HRAS. RAS-family mutations are associated with numerous types of cancer.

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 ...

Revolution Medicines launches a phase III study of zoldonrasib plus chemotherapy in first-line metastatic PDAC harboring RAS ...

A new drug targets RAS cancer-causing cells in the pancreas, nearly doubling survival rates in clinical trials. Here's how the drug works.

Patients with previously treated metastatic pancreatic cancer lived roughly twice as long when given an oral pill called ...

Revolution Medicines (NasdaqGS:RVMD) reported positive Phase 1/2 data for zoldonrasib-based combination regimens in RAS G12D ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Former Senator Ben Sasse has become an unlikely public face of a drug that researchers are ...

The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer than ...

Structural insight into KRAS conformational cycling exposed temporary binding opportunities, overturning the “undruggable” paradigm and enabling inhibitors that engage previously hidden pockets.